CA3150975A1 - Topical treatment of vitiligo by a jak inhibitor - Google Patents

Topical treatment of vitiligo by a jak inhibitor Download PDF

Info

Publication number
CA3150975A1
CA3150975A1 CA3150975A CA3150975A CA3150975A1 CA 3150975 A1 CA3150975 A1 CA 3150975A1 CA 3150975 A CA3150975 A CA 3150975A CA 3150975 A CA3150975 A CA 3150975A CA 3150975 A1 CA3150975 A1 CA 3150975A1
Authority
CA
Canada
Prior art keywords
week
patient
vitiligo
ruxolitinib
area
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3150975A
Other languages
English (en)
French (fr)
Inventor
Kathleen Butler
Jim Lee
Kang Sun
Fiona Kuo
Michael Howell
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Incyte Corp
Original Assignee
Incyte Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=73651112&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CA3150975(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Incyte Corp filed Critical Incyte Corp
Publication of CA3150975A1 publication Critical patent/CA3150975A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Dispersion Chemistry (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CA3150975A 2019-06-10 2020-06-10 Topical treatment of vitiligo by a jak inhibitor Pending CA3150975A1 (en)

Applications Claiming Priority (25)

Application Number Priority Date Filing Date Title
US201962859495P 2019-06-10 2019-06-10
US201962859506P 2019-06-10 2019-06-10
US201962859584P 2019-06-10 2019-06-10
US201962859601P 2019-06-10 2019-06-10
US201962859532P 2019-06-10 2019-06-10
US62/859,532 2019-06-10
US62/859,584 2019-06-10
US62/859,601 2019-06-10
US62/859,506 2019-06-10
US62/859,495 2019-06-10
US201962894564P 2019-08-30 2019-08-30
US201962894581P 2019-08-30 2019-08-30
US201962894496P 2019-08-30 2019-08-30
US201962894541P 2019-08-30 2019-08-30
US201962894514P 2019-08-30 2019-08-30
US62/894,496 2019-08-30
US62/894,581 2019-08-30
US62/894,541 2019-08-30
US62/894,564 2019-08-30
US62/894,514 2019-08-30
US201962911845P 2019-10-07 2019-10-07
US62/911,845 2019-10-07
US202062967879P 2020-01-30 2020-01-30
US62/967,879 2020-01-30
PCT/US2020/036985 WO2020252012A1 (en) 2019-06-10 2020-06-10 Topical treatment of vitiligo by a jak inhibitor

Publications (1)

Publication Number Publication Date
CA3150975A1 true CA3150975A1 (en) 2020-12-17

Family

ID=73651112

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3150975A Pending CA3150975A1 (en) 2019-06-10 2020-06-10 Topical treatment of vitiligo by a jak inhibitor

Country Status (10)

Country Link
US (4) US11602536B2 (cg-RX-API-DMAC10.html)
EP (1) EP3982971A4 (cg-RX-API-DMAC10.html)
JP (2) JP7532511B2 (cg-RX-API-DMAC10.html)
AU (2) AU2020290995B2 (cg-RX-API-DMAC10.html)
CA (1) CA3150975A1 (cg-RX-API-DMAC10.html)
IL (1) IL290637A (cg-RX-API-DMAC10.html)
MA (1) MA56215A (cg-RX-API-DMAC10.html)
TW (1) TW202112377A (cg-RX-API-DMAC10.html)
UA (1) UA130944C2 (cg-RX-API-DMAC10.html)
WO (1) WO2020252012A1 (cg-RX-API-DMAC10.html)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112020008850A2 (pt) 2017-11-03 2020-10-20 Aclaris Therapeutics, Inc. composto, composição farmacêutica e método para tratar uma doença mediada por jak1 e jak3
JP7591500B2 (ja) 2018-08-10 2024-11-28 アクラリス セラピューティクス，インコーポレイテッド ピロロピリミジンｉｔｋ阻害剤
US11602536B2 (en) * 2019-06-10 2023-03-14 Incyte Corporation Topical treatment of vitiligo by a JAK inhibitor
US20230364095A1 (en) * 2020-09-16 2023-11-16 Incyte Corporation Topical treatment of vitiligo
CN117279915A (zh) * 2021-02-18 2023-12-22 阿克拉瑞斯治疗股份有限公司 Jak1/3抑制剂的局部制剂及其用于特异性皮炎和其他皮肤病况的治疗的方法
JP2024509383A (ja) * 2021-02-18 2024-03-01 アクラリス セラピューティクス，インコーポレイテッド アトピー性皮膚炎及びその他の皮膚状態の治療のためのｊａｋ１／３阻害剤の局所製剤及びその使用方法
EP4389114A4 (en) * 2021-08-19 2025-09-03 Zhuhai United Laboratories Co Ltd LOCAL TOPICAL FORMULATION CONTAINING A JAK INHIBITOR OR A SALT THEREOF OR A CRYSTALLINE FORM THEREOF, PREPARATION METHOD THEREOF AND CORRESPONDING APPLICATION
CN115869321A (zh) 2021-09-28 2023-03-31 杭州中美华东制药有限公司 一种芦可替尼组合物及其制备方法

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5521184A (en) 1992-04-03 1996-05-28 Ciba-Geigy Corporation Pyrimidine derivatives and processes for the preparation thereof
ES2342240T3 (es) 1998-08-11 2010-07-02 Novartis Ag Derivados de isoquinolina con actividad que inhibe la angiogenia.
US6133031A (en) 1999-08-19 2000-10-17 Isis Pharmaceuticals Inc. Antisense inhibition of focal adhesion kinase expression
GB9905075D0 (en) 1999-03-06 1999-04-28 Zeneca Ltd Chemical compounds
GB0004890D0 (en) 2000-03-01 2000-04-19 Astrazeneca Uk Ltd Chemical compounds
CN100391958C (zh) 2001-09-19 2008-06-04 安万特医药股份有限公司 化合物
PT1441737E (pt) 2001-10-30 2006-12-29 Dana Farber Cancer Inst Inc Derivados de estrutura como inibidores da actividade do receptor de tirosina cinase flt3
PE20040522A1 (es) 2002-05-29 2004-09-28 Novartis Ag Derivados de diarilurea dependientes de la cinasa de proteina
GB0215676D0 (en) 2002-07-05 2002-08-14 Novartis Ag Organic compounds
JP2006502183A (ja) 2002-09-20 2006-01-19 アルコン，インコーポレイテッド ドライアイ障害の処置のためのサイトカイン合成インヒビターの使用
AR042052A1 (es) 2002-11-15 2005-06-08 Vertex Pharma Diaminotriazoles utiles como inhibidores de proteinquinasas
UA80767C2 (en) 2002-12-20 2007-10-25 Pfizer Prod Inc Pyrimidine derivatives for the treatment of abnormal cell growth
GB0305929D0 (en) 2003-03-14 2003-04-23 Novartis Ag Organic compounds
PE20050952A1 (es) 2003-09-24 2005-12-19 Novartis Ag Derivados de isoquinolina como inhibidores de b-raf
RU2007123675A (ru) 2004-11-24 2008-12-27 Новартис АГ (CH) Комбинации ингибиторов jak
HUE028588T2 (hu) 2005-12-13 2016-12-28 Incyte Holdings Corp Heteroaril-szubsztituált pirrolo[2,3-b]piridinek és pirrolo[2,3-b]pirimidinek mint Janus-kináz inhibitorok
EP2740731B1 (en) 2007-06-13 2016-03-23 Incyte Holdings Corporation Crystalline salts of the janus kinase inhibitor (r)-3-(4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-1h-pyrazol-1-yl)-3-cyclopentylpropanenitrile
EA202091303A3 (ru) 2010-05-21 2021-05-31 Инсайт Холдингс Корпорейшн Композиция ингибитора jak для местного применения
JP2019534304A (ja) 2016-11-10 2019-11-28 ガラパゴス・ナムローゼ・フェンノートシャップＧａｌａｐａｇｏｓ Ｎ．Ｖ． 炎症性疾患の治療のための化合物及びその医薬組成物
US11957931B2 (en) 2017-04-26 2024-04-16 Yale University Compositions and methods for treating vitiligo
US20190060311A1 (en) 2017-08-24 2019-02-28 Aclaris Therapeutics, Inc. Compositions and methods for treatment of vitiligo
WO2019191679A1 (en) 2018-03-30 2019-10-03 Incyte Corporation Biomarkers for inflammatory skin disease
CN111374639A (zh) 2018-12-28 2020-07-07 陈柏龄 败血症的菌种预测系统与方法
US20210030672A1 (en) 2019-06-10 2021-02-04 Incyte Corporation Topical treatment of vitiligo by a jak inhibitor
US11602536B2 (en) * 2019-06-10 2023-03-14 Incyte Corporation Topical treatment of vitiligo by a JAK inhibitor

Also Published As

Publication number Publication date
AU2020290995A1 (en) 2022-04-07
US20200405627A1 (en) 2020-12-31
US20220409622A1 (en) 2022-12-29
US11590138B2 (en) 2023-02-28
UA130944C2 (uk) 2026-06-24
US12233067B2 (en) 2025-02-25
TW202112377A (zh) 2021-04-01
AU2026200410A1 (en) 2026-02-12
JP2022545568A (ja) 2022-10-27
US20230355628A1 (en) 2023-11-09
AU2020290995B2 (en) 2025-12-11
JP2024105436A (ja) 2024-08-06
EP3982971A4 (en) 2023-08-16
WO2020252012A1 (en) 2020-12-17
IL290637A (en) 2022-04-01
EP3982971A1 (en) 2022-04-20
MA56215A (fr) 2022-04-20
JP7532511B2 (ja) 2024-08-13
US20200383986A1 (en) 2020-12-10
US11602536B2 (en) 2023-03-14

Similar Documents

Publication Publication Date Title
US12233067B2 (en) Topical treatment of vitiligo by a JAK inhibitor
KR20140004186A (ko) 표면활성제 조성물
US20220387447A1 (en) Formulations of testosterone and methods of treatment therewith
US10258631B2 (en) Formulations of testosterone and methods of treatment therewith
US20210030672A1 (en) Topical treatment of vitiligo by a jak inhibitor
US12589096B2 (en) Ruxolitinib formulation for reduction of itch in atopic dermatitis
US20220265572A1 (en) Remittive effects of tapinarof in the treatment of plaque psoriasis, atopic dermatitis, or radiation dermatitis
Chosidow et al. Randomized, open-labeled, non-inferiority study between ciclopiroxolamine 1% cream and ketoconazole 2% foaming gel in mild to moderate facial seborrheic dermatitis
WO2019113475A1 (en) Topical ointment formulations and their use in treating skin conditions
US20230293431A1 (en) Topical treatment of vitiligo by a jak inhibitor
EA052074B1 (ru) Топическое лечение витилиго ингибитором jak
KR20150095772A (ko) 아토피성 피부염 치료를 위한 피도티모드의 사용
US20260102359A1 (en) Combination treatment of dermal and transdermal fibrotic diseases, disorders and associated pain and inflammation
JPH0971539A (ja) 外用鎮痒剤
GB2616294A (en) Composition for use
HK1255629B (en) Composition comprising an ambora extract and a green tea extract for the treatment of psoriasis, atopic dermatitis, chronic urticaria, antihistamine-resistant pruritus and senile pruritus
HK1255629A1 (zh) 包含马马香材木(ambora)提取物和绿茶提取物的组合物用於治疗银屑病，特应性皮炎，慢性荨麻疹，抗组胺耐药瘙痒症和老年性瘙痒症

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20240610

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 5TH ANNIV.) - STANDARD

Year of fee payment: 5

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250606

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250606

D15 Examination report completed

Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D15-D126 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S REPORT

Effective date: 20250623

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - RESPONSE TO EXAMINER'S REQUISITION

Effective date: 20250917

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT

Effective date: 20251205

P13 Application amended

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED

Effective date: 20251205

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20251205

D16 Fast track examination requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D16-D106 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: ADVANCED EXAMINATION REQUESTED - PARAGRAPH 84(1)(A) OF THE PATENT RULES

Effective date: 20260508

D17 Fast track examination accepted

Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D17-D110 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: ADVANCED EXAMINATION DETERMINED COMPLIANT - PARAGRAPH 84(1)(A) OF THE PATENT RULES

Effective date: 20260508

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - VOLUNTARY AMENDMENT

Effective date: 20260508

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20260508

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT

Effective date: 20260522

P13 Application amended

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED

Effective date: 20260522

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20260522

D15 Examination report completed

Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D15-D126 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S REPORT

Effective date: 20260526

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 6TH ANNIV.) - STANDARD

Year of fee payment: 6

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20260605

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20260608